User:Km.isabelle/Fresenius Kabi

Fresenius Kabi AG is a global company operating in the healthcare sector and specializing in medicines and technologies for infusion, transfusion and clinical nutrition. Headquartered in Bad Homburg, Germany, the company has more than 40,500 employees and operates 70 sales and marketing organizations as well as around 65 production sites and compounding centers worldwide. Fresenius Kabi AG is a wholly owned subsidiary of the Fresenius SE & Co. KGaA.

Product Portfolio
Fresenius Kabi’s product portfolio includes intravenously administered generic drugs, infusion therapies and clinical nutrition products as well as the devices for administering these products. In the field of biosimilars, Fresenius Kabi focuses on autoimmune diseases and oncology. The company also offers products for collection of blood components and extracorporeal therapies in the area of transfusion medicine and cell therapies.

History
Fresenius Kabi was formed in 1999 when Fresenius Group's Pharma division was combined with the international business acquired from Pharmacia & Upjohn (Kabi). One year later, the company expanded its business into markets in Asia, Africa and Latin America. In 2004, acquisitions in South Africa and Czech Republic as well as a joint venture in Australia were implemented.

In 2005, the I.V. drug portfolio was expanded through the acquisition of the Portuguese pharmaceutical company Labesfal and the medical devices business of Clinico. To further expand this portfolio, Fresenius Kabi acquired the Argentinean pharmaceutical company Filaxis in 2006.

Further acquisitions followed in 2007 including the blood volume replacement business of Japanese pharmaceutical company Kyorin, the Chilean company Laboratorio Sanderson and the Italian company Ribbon, as well as the enteral nutrition businesses from Nestlé S.A. in France and Spain.

The I.V. generics business was further strengthened by expanding into oncology drugs with the acquisition of Dabur Pharma in 2008. In the same year, Fresenius Kabi acquired the US-based company APP pharmaceuticals.

In 2012, Fresenius Kabi acquired the transfusion technology company Fenwal and expanded its offering with a broad product portfolio for the collection and processing of blood components and for the therapeutic treatment of patient blood by apheresis systems.

Furthermore, the company added ready-to-administer prefilled syringes to its product portfolio with the acquisition of the US BD Rx business from Becton Dickinson in 2016. In 2017, Fresenius Kabi entered the biosimilars business by acquiring an R&D pipeline with a focus on oncology and autoimmune diseases and launched its first biosimilar product in Europe in 2019.